Klaus joined +ND Capital in our Lausanne office in 2021.
Prior to this, he spent 18 years in pharmaceutical industry with Boehringer Ingelheim and Ferring Pharmaceuticals, mostly in leadership positions including more than 8 years as Chief Medical Officer. At Boehringer, Klaus oversaw the successful development, global approval and launch of several novel medicines including four which have achieved blockbuster status. He gained commercial experience as General Manager for the UK & Ireland at Boehringer. Klaus is currently CEO of Vandria and a Board member at AOBiome Therapeutics and Ferring Ventures.
Klaus was a PostDoc for four years at the National Institutes of Health in Bethesda, US, conducting research in the fields of metabolic diseases and molecular biology. He received his clinical training in internal medicine and endocrinology at Heidelberg University Hospital where he teaches as an Adjunct Professor of Medicine.